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Background.Ondansetron, a serotonin-3 receptor antagonist, reduces postoperative shivering.
Drugs that reduce shivering usually impair central thermoregulatory control, and may thus be
useful for preventing shivering during induction of therapeutic hypothermia. We determined,
therefore, whether ondansetron reduces the major autonomic thermoregulatory response
thresholds (triggering core temperatures) in humans.
Methods. Control (placebo) and ondansetron infusions at the target plasma concentration of
250 ng ml1 were studied in healthy volunteers on two different days. Each day, skin and core
temperatures were increased to provoke sweating; then reduced to elicit peripheral vasocon-
striction and shivering. We determined the core-temperature sweating, vasoconstriction and
shivering thresholds after compensating for changes in mean-skin temperature. Data were
analysed using t-tests and presented as means (SDs); P<0.05 was taken as significant.
Results.Ondensetron plasma concentrations were 278 (57), 234 (55) and 243 (58) ng ml1 at the
sweating, vasoconstriction and shivering thresholds, respectively; these corresponded to 50 mg
of ondansetron which is approximately 10 times the dose used for postoperative nausea and
vomiting. Ondansetron did not change the sweating (control 37.4 (0.4)C, ondansetron 37.6
(0.3)C, P=0.16), vasoconstriction (37.0 (0.5)C vs 37.1 (0.3)C; P=0.70), or shivering threshold
(36.3 (0.5)C vs 36.3 (0.6)C; P=0.76). No sedation was observed on either study day.
Conclusions. Ondansetron appears to have little potential for facilitating induction of
therapeutic hypothermia.
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Overwhelming evidence from animal studies indicates that
even mild hypothermia provides substantial protection
against cerebral1 and myocardial ischaemia.2 In humans,
mild hypothermia improves outcome after cardiac arrest.3
Many studies of therapeutic hypothermia target core tem-
peratures between 33 and 34C. The ability to induce even
mild therapeutic hypothermia in patients having acute myo-
cardial infarction or stroke may be compromised because
small reductions in core temperature trigger aggressive ther-
moregulatory defences,4 such as shivering, which may be
harmful. Various drugs have been shown to impair thermo-
regulatory defences,5 6 but even the best have limited
efficacy and substantial side-effects. Drugs that moderate
thermoregulatory defences against cold without causing
serious side-effects would thus be of considerable clinical
interest.
Serotonin [5-hydroxytryptamine (5-HT)] is a critical ther-
moregulatory neurotransmitter.7–9 In humans, tramadol, a
5-HT reuptake inhibitor, prevents postanaesthetic shiver-
ing,10 and in non-anaesthetized individuals, it decreases
the core temperature that triggers shivering (the shivering
threshold) by approximately 0.9C.11
The role of the 5-HT1A receptor subtype in
5-HT-mediated hypothermia is well established largely
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based on data using 8-hydroxy-[N-n-dipropyl-N-(30-iodo-
20-propenyl) amino] tetralin (8-OH-DPAT) as a ligand.12
Although the evidence of involvement of 5-HT3 receptor
subtype in 5-HT-mediated thermoregulation is scarce, a
serotonin 5-HT3 agonist can induce hyperthermia in rats,
7
which is attenuated by pretreatment with a 5-HT3 antago-
nist. Furthermore, when given alone, 5-HT3 antagonists
induce hypothermia.9 As one can expect from these effects
in rats, 5-HT3 antagonists prevent postanaesthetic shivering
in humans.13 They may thus inhibit shivering, perhaps
enough to facilitate induction of therapeutic hypothermia.
Thus we tested the hypothesis that ondansetron, a prototy-
pical 5-HT3 antagonist, reduces the sweating, vasoconstric-
tion, and shivering thresholds—and that the reduction is
clinically important (i.e. >1C).
Methods
With approval of the Human Studies Committee at the
University of Louisville and written informed consent,
we studied 10 healthy volunteers. None was obese, taking
medication, or had a history of thyroid disease, dysautono-
mia or Raynaud’s syndrome.
Each volunteer was studied on two randomly assigned
days: (1) control (placebo) and (2) ondansetron hydrochlor-
ide (GlaxoSmithKline, Research Triangle Park, NC, USA)
at a target plasma concentration of 250 ng ml1. Volunteers
were blinded as to which solution they received on each
study day. The volunteers fasted for 8 h before the start of
each study day. They dressed minimally and rested supine
on a standard operating room table. Ambient temperature
was maintained near 21C and humidity at 25%.
A 14 gauge catheter was inserted in a right antecubital
vein for blood sampling and an 18 gauge catheter was
inserted in a left forearm vein for ondansetron or placebo
administration. Blood for ondansetron analysis was sampled
from the catheter inserted in right antecubital vein before
drug administration (blank sample) and at each threshold.
Blood was centrifuged, and the plasma was removed and
stored at 40C until analysis.
Ondansetron was infused using a target-controlled infu-
sion with a Stanpump program based on pharmacokinetic
data from Colthup and colleagues14 and de Alwis and col-
leagues15 at a target plasma concentration of 250 ng ml1.
This corresponds to 50 mg of ondansetron over the
approximately 2.5 h study period. A similar volume of nor-
mal saline was infused on the control day. The infusion
began at the start of thermal manipulation and continued
until shivering was detected.
Skin and core temperatures were gradually increased with
an Allon circulating-water garment (MTRE, North Indus-
trial Park, Israel) and a whole-body convective-air warming
coverlet and air heater-blower unit (Bair Hugger Model 250,
Augustine Medical, Inc., Eden Prairie, MN, USA) until
sweating occurred. Subsequently, skin and core temperature
were decreased with an Allon circulation-water garment and
convective-air cooling coverlet (PolarAir, Augustine
Medical Inc., Eden Prairie, MN, USA) until shivering
occurred. The volunteer’s body was insulated with the
warming and cooling devices mentioned; except for the
head, and right forearm and hand, which were used for
fingertip blood flow measurement.
Core temperature was measured at the tympanic
membrane using Mon-a-therm thermocouples (Tyco-
Mallinckrodt Anesthesiology Products, Inc., St Louis,
MO, USA). The aural probes were inserted by the volunteers
until they felt the thermocouple touch the tympanic
membrane; appropriate placement was confirmed when
volunteers easily detected a gentle rubbing of the attached
wire. The aural canal was occluded with cotton and taped in
place.
Mean skin-surface temperature and cutaneous heat
transfer were calculated from measurements at 15 area-
weighted sites. Temperatures were recorded at 1 min
intervals from thermocouples connected to calibrated
Iso-Thermex thermometers having an accuracy of 0.1C
and a precision of 0.01C (Columbus Instruments, Corp.,
Columbus, OH, USA).
Sweating was continuously quantified on the left upper
chest using a ventilated capsule.4 We considered a sweating
rate >40 g m2 h1 for at least 5 min to be significant.16
Absolute right middle fingertip blood flow was quantified
using venous-occlusion volume plethysmography at 5 min
intervals.17 The vasoconstriction threshold was determined
post hoc by an observer blinded to treatment and core
temperature.
As in previous similar studies,16 we used systemic oxygen
consumption to quantify shivering. A Deltatrac metabolic
monitor (SensorMedics Corp., Yorba Linda, CA, USA) was
used in canopy mode. Initiation of the shivering threshold
was determined post hoc by an observer blinded to treatment
and core temperature. The same observer determined the
shivering threshold for all subjects. End-tidal carbon dioxide
was sampled from a catheter inserted into one nostril; gas
removed from the catheter was returned to the canopy of the
metabolic monitor.
Heart rate, end-tidal carbon dioxide and oxyhaemoglobin
saturation (SpO
2
) were measured continuously, and blood
pressure was determined oscillometrically at 5 min intervals
at the left ankle.
An investigator blinded to core temperature and treatment
evaluated sedation using the responsiveness component of
the observer’s assessment of alertness/sedation (OAA/S)
score (Table 1)18 at 15 min before starting drug adminis-
tration, before thermal manipulation started and at each
threshold.
Before extraction, plasma samples for ondansetron
analysis were allowed to thaw at room temperature and
vortexed. To 1 ml of plasma, 1 ml 0.1 M sodium phosphate
buffer, pH 6.0 and internal standard (prazosine hydrochlor-
ide, Sigma–Aldrich, USA) was added and vortexed. Clean
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Screen solid phase extraction columns (CSDAU-203, World
Wide Monitoring, United Chemical Technologies, Inc.,
Bristol, PA, USA) were preconditioned with 3 ml of
methanol, 3 ml of deionized water and 3 ml of 0.1 M
sodium phosphate buffer before the plasma samples were
loaded (about 0.5 ml min1). The cartridges were rinsed
with 3 ml of deionized water, 2 ml of 1 M acetic acid,
3 ml of methanol and then dried under vacuum for at
least 5 min. The extracts were then eluted from the cart-
ridge with 3 ml of freshly prepared dichloromethane–
isopropanol–ammonium hydroxide 25% (39:10:1; vol:
vol:vol, prepared with sonication) by gravity filtration.
The eluate was evaporated to dryness under nitrogen
stream in a water bath at about 40C. The residues were
redissolved in 200 ml mobile phase mixture, briefly mixed
in an ultrasonic bath, and loaded into auto-sampler vials.
Samples were analyzed by HPLC (Merck-Hitachi, L6200A
and AS-2000A, Hitachi, Ltd, Tokyo, Japan) with UV detec-
tion (Merck-Hitachi, DAD L-4500) at 250 nm. Aliquots of
20 ml were injected onto a Nucleodur 100-5 CN-RP
(Macherey-Nagel, CH), 250 mm, 4 mm ID column with
an 8 mm precolumn. The mobile phase consisted of 40%
acetonitrile, 60% 20 mM bisodiumphosphate buffer, pH 5.4.
The flow rate was 1.5 ml min1 and operating temperatures
were 35C. The data were processed with proprietary HPLC
control software (Merck-Hitachi, Model D-7000, Hitachi
Instruments, Inc., San Jose, CA, USA).
Retention times of the internal standard and ondansetron
(Zofran, GlaxoSmithKline plc, Middlesex, UK) were 2.96
and 3.36 min, respectively. Calibration curves with spiked
and extracted plasma passed through the origin and were
linear in the calibration range 150–400 ng ml1 with corre-
lation coefficient values of r2>0.99. The intraday and inter-
day coefficients of variation were 2.5 and 3% for quality
control samples containing 250 ng ml1 ondansetron,
respectively. For ondansetron, the limit of quantification
(S/N=10) was 15 ng ml1 and the recovery was >95%.
Statistical analysis
The cutaneous contribution to the thermoregulatory
responses—sweating,19 vasoconstriction and shivering—is
linear.20 We thus used measured skin and core temperatures
in C at each threshold to calculate the core-temperature
threshold that would have been observed had skin been
maintained at a single designated temperature. For this
purpose, we used equation (1) that corrects core temperature
for cutaneous temperature, providing response thresholds
that would have been observed at a designated core
temperature.
TcoreðcalculatedÞ=Tcore þ b
1b
 
½T skinTskinðdesignatedÞ ð1Þ
We have previously described the derivation and valida-
tion of this equation.16 We used a b of 0.1 for sweating19
and a b of 0.2 for vasoconstriction and shivering.20 The
designated skin temperature was set at 34C, a typical
intraoperative value.
We determined that a sample size of 10 would detect a
0.5C difference in shivering thresholds between control
and drug days with 90% power. Based on a similar study
conducted with the same design in our laboratory with dox-
apram,21 we assumed that the difference in shivering thresh-
olds on the two study days would have a SD of 0.44 and
correlation of 0.75.
Oxygen consumption and calculated respiratory quotient
were averaged during baseline (before commencement of
drug infusion), during the cooling phase before shivering
and during shivering, respectively. The averaged values
were then compared with two-way ANOVA (two factors;
drug, period) and post hoc Bonferroni/Dunn tests.
Ambient temperature, humidity, mean arterial pressure,
heart rate, SpO
2
and end-tidal carbon dioxide on each study
day were averaged within each volunteer across the warm-
ing and cooling periods; the resulting values were then
averaged among volunteers. Results for each study day
were compared using Wilcoxon signed-rank tests or paired
t-tests. Plasma concentrations of ondansetron at each thresh-
old were compared using one-way ANOVA. All results are
presented as means (SD) or median (range), as appropriate;
P<0.05 was considered statistically significant.
Results
Seven of the participants were males and three were
females. They were 24 (19–31) yr old, weighed
73 (14) kg, and were 174 (7) cm tall. Among the factors
that might have influenced the thermoregulatory thresholds,
ambient temperature was significantly higher on ondanse-
tron days than on the control days, but the average difference
was only 0.7C (P=0.004; Table 2).
Plasma ondansetron concentrations were similar at each
threshold, 250 ng ml1. The median dose of ondansetron
was 49 mg and ranged from 36 to 70 mg. None of the study
participants was sedated at any time on either study day, and
OAA/S scores remained 5 for all volunteers throughout the
study.
The sweating thresholds were similar on the control
[37.4 (0.4)C] and ondansetron [37.6 (0.3)C] days
(P=0.16) [mean (SD)]. Ondansetron did not alter either
the vasoconstriction threshold [control 37.0 (0.5)C;
Table 1. Responsive component of the OAA/S scale
Score Responsiveness
5 Responds readily to name spoken in normal tone
4 Lethargic response to name spoken in normal tone
3 Responds only after name is spoken loudly, repeatedly, or both
2 Responds only after mild prodding or shaking
1 Does not respond to mild prodding or shaking
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ondansetron 37.1 (0.3)C; P=0.70] or the shivering thresh-
old [control 36.3 (0.5)C; ondansetron 36.3 (0.6)C;
P=0.76] (Table 3 and Fig. 1).
Discussion
Plasma ondansetron concentrations were similar at each of
the three thermoregulatory thresholds and were near our
target concentration of 250 ng ml1. The Stanpump
program, based on pharmacokinetic data of Colthup and
colleagues14 and de Alwis and colleagues15 thus proved
reliable. According to the 2003 edition of the Physician’s
Desk Reference, a single 32 mg bolus of ondansetron—the
dose used for prevention of chemotherapy-induced nausea
and vomiting—yields a maximum plasma concentration of
264 ng ml1. We thus chose a target ondansetron plasma
concentration of 250 ng ml1. Our modelling suggested that
the total dose after a 5 h infusion would be 60 mg in a 70 kg
volunteer, which is less than that used for prophylaxis
of chemotherapy-induced nausea and emesis in clinical
trials.22 In fact, the total dose we used averaged 49 (12) mg.
We targeted a plasma ondansetron concentration that
might be used for treatment of chemotherapy-induced
nausea and vomiting; therefore, our volunteers received
roughly 10 times the dose normally used for prevention
of postoperative nausea and vomiting.23 But even at this
high concentration, there was no perceptible effect of
ondansetron on the sweating, vasoconstriction or shivering
thresholds. It is thus apparent that ondansetron alone cannot
be used to facilitate induction of therapeutic hypothermia,
and there is little reason to believe that it will prove to be a
useful adjunct to other anti-shivering medications.
Meta-analysis indicates that meperidine 25 mg, clonidine
150 mg, ketanserin 10 mg and doxapram 100 mg are effec-
tive anti-shivering agents.24 Nalbuphine also prevents post-
operative shivering25 and has been formally evaluated for
shivering threshold suppression.26 Several drugs that are
unquestionably effective for postoperative shivering actu-
ally reduce the shivering threshold only slightly. For exam-
ple, clonidine and doxapram reduce the shivering
threshold only about 0.5C, but are nonetheless effective
anti-shivering agents. The reason, presumably, is that
many postoperative patients have core temperatures only
slightly below the normal shivering threshold, which is
about 35.5C.27 Other effective anti-shivering drugs reduce
the shivering threshold even more, typically about 1C
(Table 4). Ondansetron thus appears to be unique in report-
edly reducing the incidence of postoperative shivering,13 but
not in reducing the shivering threshold, even at doses
10 times those used for treatment of postoperative nausea
and vomiting.
Postoperative rhythmic shivering-like muscular activity
is a complex phenomenon. Most of such activity is thermo-
regulatory, and most of it is normal shivering. However,
some are expressed as tonic stiffening that occurs when
residual concentrations of volatile anaesthesia are 0.2–0.4
Table 2. Potential confounding factors. Values were recorded at 5 min intervals
and averaged over the sweating-to-shivering period. Results are presented as
medians (range); results were compared with Wilcoxon signed-rank test
Control day Ondansetron day P-value
Mean arterial blood
pressure (mm Hg)
88 (84–106) 92 (72–102) 0.867
Heart rate (beats min1) 71 (57–95) 72 (55–88) 0.754
End-tidal carbon
dioxide (kPa)
5.3 (5.2–5.7) 5.5 (4.4–6.1) 0.863
Oxygen saturation (%) 98 (97–99) 97 (96–98) 0.375
Ambient temperature (C) 24.6 (24.0–26.3) 25.7 (24.8–26.7) 0.004
Relative humidity (%) 28.2 (5.4–40.6) 13.1 (4.5–38.5) 0.160
Table 3. Plasma ondansetron concentrations, mean-skin temperatures, core
temperatures and calculated thermoregulatory thresholds. Thresholds were cal-
culated based on a designated mean-skin temperature of 34C. Results are
presented as means (SD) (range). Only the threshold values were statistically
compared, and none differed significantly
Control Ondansetron
Sweating
Mean skin (C) 36.7 (0.5) 36.9 (0.3)
Core (C) 37.1 (0.4) 37.2 (0.3)
Threshold (C) 37.4 (0.4) 37.6 (0.3)
Ondansetron concentration (ng ml1) – 278 (57) (226–380)
Vasoconstriction
Mean skin (C) 33.5 (1.2) 33.6 (0.7)
Core (C) 37.1 (0.3) 37.2 (0.3)
Threshold (C) 37.0 (0.5) 37.1 (0.3)
Ondansetron concentration (ng ml1) – 234 (55) (161–325)
Shivering
Mean skin (C) 30.7 (1.3) 30.4 (1.8)
Core (C) 37.1 (0.3) 37.1 (0.3)
Threshold (C) 36.3 (0.5) 36.3 (0.6)
Ondansetron concentration (ng ml1) – 243 (58) (178–338)
37.5
37.0
36.5
36.0
35.5
35.0
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Fig 1 Shivering thresholds in 10 healthy volunteers. The open circles
show the shivering threshold for each volunteer on the control and
ondansetron study days; the filled squares are the group means (SD). The
shivering threshold was similar on the control day and ondansetron day,
P=0.76.
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of the minimum alveolar concentration. Other tremors are
manifested as clonic tremors similar to pathological clonus
or physiological action tremor, which appear to be triggered
by low concentrations (i.e. 0.1 minimum alveolar concen-
tration) of volatile anaesthetics.28 Other shivering-like
tremors are not thermoregulatory at all29 and appear to be
facilitated by pain.30 It is thus possible that 5-HT3 antago-
nists inhibit non-thermoregulatory shivering-like activity.
A limitation of our study was that the mean ambient
temperature was significantly greater on the ondansetron
day than the control day. However, the temperatures dif-
fered by only 0.6C. More importantly, skin temperature,
except for the head and the right forearm, was deliberately
manipulated throughout the study period. Skin temperature
contributes 10% to autonomic control of sweating19 and
20% to control of vasoconstriction and shivering,20 and
thermal sensitivity of the face is greater than that of the
remaining skin surface.31 However, the lower arm and
face make up a small portion of the total skin surface.
We have previously demonstrated that neither arm nor
face warming influences the shivering threshold in non-
anaesthetized human volunteers.32 The small difference in
ambient temperature on the two study days is thus unlikely
to compromise the thermoregulatory threshold outcomes.
In summary, ondansetron at a plasma concentration of
250 ng ml1, that is at a dose near that used to treat
chemotherapy-induced nausea and emesis, did not signifi-
cantly alter the core-temperature thresholds triggering
sweating, vasoconstriction or shivering. The drug, therefore,
appears to have little potential for facilitating induction of
therapeutic hypothermia.
Acknowledgements
Supported by NIH Grant GM 061655 (Bethesda, MD, USA), the Gheens
Foundation (Louisville, KY, USA), the Joseph Drown Foundation
(Los Angeles, CA, USA), and the Commonwealth of Kentucky Research
Challenge Trust Fund (Louisville, KY, USA). Mallinckrodt Anesthesiology
Products (St Louis, MO, USA) donated the thermocouples we used in this
study; MTRE Advanced Technologies, Ltd (North Industrial Park, Israel)
donated the Allon circulating-water system; Arizant Medical, Inc. (Eden
Prairie, MN, USA) donated the forced-air warming and cooling systems.
We thank Gilbert Haugh, M.S., for statistical analyses of the data and Nancy
Alsip, Ph.D., for editorial assistance (both of the University of Louisville).
References
1 Popovic R, Liniger R, Bickler PE. Anesthetics and mild hypother-
mia similarly prevent hippocampal neuron death in an in vitro
model of cerebral ischemia. Anesthesiology 2000; 92: 1343–9
2 Dae MW, Gao DW, Sessler DI, Chair K, Stillson CA. Effect of
endovascular cooling on myocardial temperature, infarct size,
and cardiac output in human-sized pigs. Am J Physiol Heart Circ
Physiol 2002; 282: H1584–91
3 Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose
survivors of out-of-hospital cardiac arrest with induced hypother-
mia. N Engl J Med 2002; 346: 557–63
4 Lopez M, Sessler DI, Walter K, Emerick T, Ozaki M. Rate and
gender dependence of the sweating, vasoconstriction, and shiver-
ing thresholds in humans. Anesthesiology 1994; 80: 780–8
5 Talke P, Tayefeh F, Sessler DI, et al. Dexmedetomidine does not
alter the sweating threshold, but comparably and linearly reduces
the vasoconstriction and shivering thresholds. Anesthesiology
1997; 87: 835–41
6 Alfonsi P, Adam F, Passard A, et al. Nefopam, a nonsedative
benzoxazocine analgesic, selectively reduces the shivering thresh-
old in unanesthetized subjects. Anesthesiology 2004; 100: 37–43
7 Mazzola-Pomietto P, Aulakh CS, Murphy DL. Temperature, food
intake, and locomotor activity effects of a 5-HT3 receptor agonist
and two 5-HT3 receptor antagonists in rats. Psychopharmacology
(Berl) 1995; 121: 488–93
8 Pinelli A, Trivulzio S, Tomasoni L. Effects of ondansetron admin-
istration on opioid withdrawal syndrome observed in rats. Eur J
Pharmacol 1997; 340: 111–19
9 Kandasamy SB. Effect of ondansetron and ICS 205-930 on
radiation-induced hypothermia in rats. Radiat Res 1997; 147:
741–6
10 De Witte J, Rietman GW, Vandenbroucke G, Deloof T. Post-
operative effects of tramadol administered at wound closure.
Eur J Anaesthesiol 1998; 15: 190–5
11 De Witte JL, Kim JS, Sessler DI, Bastanmehr H, Bjorksten AR.
Tramadol reduces the sweating, vasoconstriction, and shivering
thresholds. Anesth Analg 1998; 87: 173–9
12 Hjorth S. Hypothermia in the rat induced by the potent seroto-
ninergic agent 8-OH-DPAT. J Neural Transm 1985; 61: 131–5
13 Powell RM, Buggy DJ. Ondansetron given before induction of
anesthesia reduces shivering after general anesthesia. Anesth
Analg 2000; 90: 1423–7
14 Colthup PV, Felgate CC, Palmer JL, Scully NL. Determination
of ondansetron in plasma and its pharmacokinetics in the
young and elderly. J Pharm Sci 1991; 80: 868–71
15 de Alwis DP, Aarons L, Palmer JL. Population pharmacokinetics
of ondansetron: a covariate analysis. Br J Clin Pharmacol 1998;
46: 117–25
16 Matsukawa T, Kurz A, Sessler DI, et al. Propofol linearly reduces
the vasoconstriction and shivering thresholds. Anesthesiology
1995; 82: 1169–80
17 Rubinstein EH, Sessler DI. Skin-surface temperature gradients
correlate with fingertip blood flow in humans. Anesthesiology
1990; 73: 541–5
18 Chernik DA, Gillings D, Laine H, et al. Validity and reliability of the
Observer’s Assessment of Alertness/Sedation Scale: study with
intravenous midazolam. J Clin Psychopharmacol 1990; 10: 244–51
19 Nadel ER, Horvath SM, Dawson CA, Tucker A. Sensitivity to
central and peripheral thermal stimulation in man. J Appl Physiol
1970; 29: 603–9
Table 4. Drugs used for postoperative shivering and their effects on the shiver-
ing threshold. The ‘Dose or concentration’ column refers to threshold reduction.
Various doses were used for treatment of shivering, but usually as a bolus
without controlling pharmacokinetics or measurement of plasma drug concen-
tration; only selected examples of shivering treatment are included
Treatment of
shivering
Reduction in
shivering threshold
(C)
Dose or
concentration
(ng ml1)
Clonidine Piper and colleagues,33
Horn and colleagues29
0.6 (0.3)34 75 mg
Nefopam Bilotta and colleagues35 0.9 (0.4)6 55
Tramadol De Witte and colleagues36 0.911 205
Meperidine Piper and colleagues,33
Wang and colleagues25
1.237 0.3
Doxapram Singh and colleagues38 0.521 2.6
Nalbuphine Wang and colleagues25 1.126 30
Komatsu et al.
736
20 Cheng C, Matsukawa T, Sessler DI, et al. Increasing mean skin
temperature linearly reduces the core-temperature thresholds
for vasoconstriction and shivering in humans. Anesthesiology 1995;
82: 1160–8
21 Komatsu R, Sengupta P, Cherynak G, et al. Doxapram only slightly
reduces the shivering threshold in healthy volunteers. Anesth
Analg 2005; 101: 1368–73
22 Grunberg SM, Stevenson LL, Russell CA, McDermed JE. Dose
ranging phase I study of the serotonin antagonist GR38032F for
prevention of cisplatin-induced nausea and vomiting. J Clin Oncol
1989; 7: 1137–41
23 Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six
interventions for the prevention of postoperative nausea and
vomiting. N Engl J Med 2004; 350: 2441–51
24 Kranke P, Eberhart LH, Roewer N, Tramer MR. Pharmacological
treatment of postoperative shivering: a quantitative systematic
review of randomized controlled trials. Anesth Analg 2002; 94:
453–60
25 Wang JJ, Ho ST, Lee SC, Liu YC. A comparison among nalbuphine,
meperidine, and placebo for treating postanesthetic shivering.
Anesth Analg 1999; 88: 686–9
26 Greif R, Laciny S, Rajek AM, et al. Neither nalbuphine nor
atropine possess special antishivering activity. Anesth Analg
2001; 93: 620–7
27 Lopez M, Sessler DI, Walter K, Emerick T, Ozaki M. Rate
and gender dependence of the sweating, vasoconstriction, and
shivering thresholds in humans. Anesthesiology 1994; 80: 780–8
28 Sessler DI, Rubinstein EH, Moayeri A. Physiological responses to
mild perianesthetic hypothermia in humans. Anesthesiology 1991;
75: 594–610
29 Horn EP, Sessler DI, Standl T, et al. Non-thermoregulatory
shivering in patients recovering from isoflurane or desflurane
anesthesia. Anesthesiology 1998; 89: 878–86
30 Horn E-P, Schroeder F, Wilhelm S, et al. Postoperative pain
facilitates non-thermoregulatory tremor. Anesthesiology 1999;
91: 979–84
31 Burke WE, Mekjavic IB. Estimation of regional cutaneous cold
sensitivity by analysis of the gasping response. J Appl Physiol
1991; 71: 1933–40
32 Doufas AG, Wadhwa A, Lin CM, et al. Neither arm nor face
warming reduces the shivering threshold in unanesthetized
humans. Stroke 2003; 34: 1736–40
33 Piper SN, Maleck WH, Boldt J, et al. A comparison of urapidil,
clonidine, meperidine and placebo in preventing postanesthetic
shivering. Anesth Analg 2000; 90: 954–7
34 Delaunay L, Bonnet F, Liu N, et al. Clonidine comparably
decreases the thermoregulatory thresholds for vasoconstriction
and shivering in humans. Anesthesiology 1993; 79: 470–4
35 Bilotta F, Pietropaoli P, Sanita R, Liberatori G, Rosa G. Nefopam
and tramadol for the prevention of shivering during neuraxial
anesthesia. Reg Anesth Pain Med 2002; 27: 380–4
36 de Witte J, Deloof T, de Veylder J, Housmans PR. Tramadol in
the treatment of postanesthetic shivering. Acta Anaesthesiol Scand
1997; 41: 506–10
37 Doufas AG, Lin CM, Suleman MI, et al. Dexmedetomidine and
meperidine additively reduce the shivering threshold in humans.
Stroke 2003; 34: 1218–23
38 Singh P, Dimitriou V, Mahajan RP, Crossley AW. Double-blind
comparison between doxapram and pethidine in the treatment of
postanaesthetic shivering. Br J Anaesth 1993; 71: 685–8
Ondansetron and the shivering threshold
737
